Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1441552 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL1441555 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL19384405 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL1442836 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL1442839 | 0.96 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL12819385 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL12819830 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL12819942 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL6072643 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1TP53TSHRNPC1 | |
| SCHEMBL16059198 | 0.82 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | SMN1; SMN2 3448/4885ALDH1A1 477/4885TP53 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.